Given the potential therapeutic benefit of MYC-family transcription factor inhibition in a wide variety of cancers, we investigated the effects of BET inhibition in neuroblastoma, an aggressive pediatric cancer associated with a high frequency of MYCN gene amplification. This evidence concerns the gene MYCN and cancer.